TPI Deficiency (TPI Df) is an untreatable glycolytic enzymopathy that results in hemolytic anemia, progressive muscular impairment and irreversible brain damage. Although there is a “common” mutation (TPIE105D), other pathogenic mutations have been described. We identified patients with who are compound heterozygous for a newly-described mutation, TPIQ181P, and the common TPIE105D mutation. Intriguingly, these patients lack neuropathy or cognitive impairment. We initiated biochemical and structural studies of TPIQ181P. Surprisingly, purified TPIQ181P protein has markedly impaired catalytic properties while crystallographic studies demonstrate that TPIQ181P results in a highly disordered catalytic lid. We propose that genetic complementation is occurring between the two alleles, one with little activity (TPIQ181P) and one with low stability (TPIE105D). Consistent with this, TPIQ181P/E105D fibroblasts exhibit a significant reduction in TPI protein but much higher protein than TPIE105D/E105D fibroblasts. These data suggest that impaired stability, and not catalytic activity, is a better predictor of TPI Df severity. Lastly, we tested two recently discovered chemical modulators of mutant TPI stability and observed a significant increase in TPI in TPIQ181P/E105D patient cells.
Itavastatin and Resveratrol increase triosephosphate isomerase protein (TPI) in a newly identified variant, TPIQ181P, that confers TPI deficiency
- Award Group:
- Funder(s): NIH
- Award Id(s): R21 AG059385
- Funder(s):
Currently Viewing Accepted Manuscript - Newer Version Available
- Split-screen
- Views Icon Views
- Open the PDF for in another window
-
Article Versions Icon
Versions
- Version of Record 17 May 2022
- Accepted Manuscript 22 March 2022
- Share Icon Share
-
Tools Icon
Tools
- Search Site
Andrew P. VanDemark, Stacy L. Hrizo, Samantha L. Eicher, Jules Kowalski, Tracey D. Myers, Megan R. Pfeifer, Kacie N. Riley, Dwight D. Koeberl, Michael J. Palladino; Itavastatin and Resveratrol increase triosephosphate isomerase protein (TPI) in a newly identified variant, TPIQ181P, that confers TPI deficiency. Dis Model Mech 2022; dmm.049261. doi: https://doi.org/10.1242/dmm.049261
Download citation file:
Advertisement
Valuing peer review at Disease Models & Mechanisms
We would like to thank our peer reviewers who contributed their time and expertise in 2023. In her latest Editorial, Editor-in-Chief Liz Patton has outlined why we continue to value our peer reviewers dedication.
Subject collection: Building advocacy into research
DMM’s new series - Building advocacy into research - features interviews, ‘The Patient’s Voice’, with patients and advocates for a range of disease types, with the aim of supporting the highest quality research for the benefit of all patients affected by disease.
Travelling Fellowships for early-career researchers
DMM and its sister journals offer Travelling Fellowships of up to £3,000 to graduate students and post-doctoral researchers wishing to make collaborative visits to other laboratories. Find out more about our Travelling Fellowships and read stories from previous grant recipients.
Read & Publish Open Access publishing: what authors say
We have had great feedback from authors who have benefitted from our Read & Publish agreement with their institution and have been able to publish Open Access with us without paying an APC. Read what they had to say.
The Forest of Biologists
Our Publisher Claire Moulton recently visited the two Woodland Trust UK sites where we are planting new native trees for published Research and Review papers and protecting ancient woodland on behalf of our peer reviewers.
Other journals from
The Company of Biologists